Gastrointestinal Cancer | Specialty

BRAF-Mutated Colorectal Cancer

July 23rd 2014

Second-Line Treatment Options in mCRC

July 23rd 2014

Future Analyses From the 80405 mCRC Trial

July 23rd 2014

Conducting Extended RAS Testing in CRC

July 23rd 2014

Extended RAS Testing in Metastatic CRC

July 23rd 2014

CALGB 80405 Trial Results in mCRC

July 23rd 2014

Introduction: Bevacizumab Versus Cetuximab in mCRC

July 23rd 2014

Dr. Hoff on Delivering Chemotherapy Until Progression Versus Complete Stop in mCRC

July 22nd 2014

Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses a meta-analysis of randomized trials that examined the effect of chemotherapy delivered until progression versus complete stop on the overall survival of patients with metastatic colorectal cancer (mCRC).

Immunotherapy Combination Receives Breakthrough Designation for Pancreatic Cancer

July 21st 2014

The combination of the immunotherapy CRS-207 and the vaccine GVAX Pancreas has received a breakthrough therapy designation from the FDA for its potential as a treatment for patients with metastatic pancreatic cancer.

Dr. Abou-Alfa Discusses the STORM Trial in HCC

July 17th 2014

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the findings from the STORM trial, a phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC).

Dr. Ilson Discusses the Findings of the RTOG 0436 Trial

July 8th 2014

David H. Ilson, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the conclusions of the RTOG 0436 trial, a phase III trial of cisplatin, paclitaxel, and radiation with or without cetuximab in the non-operative treatment of esophageal cancer.

Dr. Fakih on Advances in Liver-Directed Therapies in CRC

July 3rd 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses recent advances in liver-directed therapies in colorectal cancer (CRC).

Dr. Arnold on a Phase III Trial Examining Options for Maintenance Therapy in mCRC

July 2nd 2014

Dirk Arnold, MD, director, Department of Medical Oncology, Tumour Biology Centre, Freiburg, Germany, discusses a phase III trial looking at options for maintenance therapy for metastatic colorectal cancer (mCRC).

Dr. Yoshino Discusses the Safety Profile of TAS-102

June 30th 2014

Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo, with best supportive care, in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.

Cetuximab, Bevacizumab Equivalent as First-Line Therapy in KRAS Wild-Type mCRC

June 28th 2014

A head-to-head comparison of cetuximab and bevacizumab in a phase III trial that was nearly 10 years in the making showed equivalence for chemotherapy plus either agent in terms of OS, PFS, and response rates for patients with certain previously untreated metastatic colorectal cancers.

Palliative Resection Associated With Improved Survival in mCRC

June 28th 2014

Initial treatment with surgical resection of the primary tumor followed by systemic treatment yielded a 4.7-month OS benefit compared with the same treatments administered in the reverse order in patients with mCRC receiving palliative care.

Dr. Bendell Discusses a Phase III Study of Apatinib in Gastric Cancer

June 28th 2014

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses a randomized phase III placebo-controlled trial that explored apatinib as a treatment for patients with advanced gastric cancer.

Dr. Venook Discusses Implications of the 80405 Study

June 28th 2014

Alan P. Venook, MD, a professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco, discusses implications from the CALGB/SWOG 80405 trial on the targeted therapies administered in colorectal cancer.

TAS-102 Monotherapy Improves OS, PFS in Refractory mCRC

June 28th 2014

Treatment with the oral nucleoside TAS-102 significantly extended OS and PFS for patients with metastatic colorectal cancer refractory to standard therapies.

Dr. Wang-Gillam Discusses the NAPOLI-1 Trial in Pancreatic Cancer

June 28th 2014

Andrea Wang-Gillam, MD, PhD, from the Siteman Cancer Center, discusses the trial design and results of the phase III NAPOLI-1 trial that examined MM-398 with 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer following progression on gemcitabine-based therapy.